These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10475797)

  • 1. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.
    Lawlor E; Columb G
    N Engl J Med; 1999 Sep; 341(10):762; author reply 763. PubMed ID: 10475797
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.
    Bonis PA
    N Engl J Med; 1999 Sep; 341(10):763. PubMed ID: 10475798
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.
    Kenny-Walsh E
    N Engl J Med; 1999 Apr; 340(16):1228-33. PubMed ID: 10210705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus associated with Irish anti-D immunoglobulin.
    Commun Dis Rep CDR Wkly; 1994 Mar; 4(9):39. PubMed ID: 7513236
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus and intravenous anti-D immunoglobulin.
    Commun Dis Rep CDR Wkly; 1995 Jun; 5(24):111, 114. PubMed ID: 7542122
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*.
    Itakura J; Nagayama K; Enomoto N; Hamano K; Sakamoto N; Fanning LJ; Kenny-Walsh E; Shanahan F; Watanabe M
    J Viral Hepat; 2005 Nov; 12(6):594-603. PubMed ID: 16255760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
    Bjøro K; Frøland SS; Yun Z; Samdal HH; Haaland T
    N Engl J Med; 1994 Dec; 331(24):1607-11. PubMed ID: 7526215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C infection from anti-D immunoglobulin.
    Power JP; Davidson F; O'Riordan J; Simmonds P; Yap PL; Lawlor E
    Lancet; 1995 Aug; 346(8971):372-3. PubMed ID: 7677904
    [No Abstract]   [Full Text] [Related]  

  • 9. Extrahepatic immunological manifestations of hepatitis C virus in dialysis patients.
    Canavese C; Hollò Z; Ciccone G; Ghisetti V; Barbui A; Fop F; Martina G; Forgnone F; Novo P; Thea A; Grill A; Marchiaro G
    J Nephrol; 2000; 13(5):352-9. PubMed ID: 11063139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peak impact of an Egyptain outbreak of hepatitis C virus: has it passed or has not yet occurred?
    El Sherbini A; Mohsen SA; Hasan W; Mostafa S; El Gohary K; Moneib A; Abaza AH
    Liver Int; 2007 Aug; 27(6):876-7. PubMed ID: 17617132
    [No Abstract]   [Full Text] [Related]  

  • 11. Seronegative hepatitis C virus infection, not just RNA detection.
    Stapleton JT; Schmidt WN; Katz L
    J Infect Dis; 2004 Aug; 190(3):651-2. PubMed ID: 15243946
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C infection and recent diagnostic modalities.
    Shahi SK; Ranga S; Mahajan R
    Indian J Pathol Microbiol; 2000 Apr; 43(2):103-4. PubMed ID: 11217263
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies.
    Daniel HD; Abraham P; Raghuraman S; Vivekanandan P; Subramaniam T; Sridharan G
    J Clin Microbiol; 2005 Apr; 43(4):1977-8. PubMed ID: 15815036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study.
    Fanning L; Kenny-Walsh E; Levis J; Choudhury KR; Cannon B; Sheehan M; Whelton M; Shanahan F
    Hepatology; 2000 Jan; 31(1):225-9. PubMed ID: 10613750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial.
    Piazza M; Sagliocca L; Tosone G; Guadagnino V; Stazi MA; Orlando R; Borgia G; Rosa D; Abrignani S; Palumbo F; Manzin A; Clementi M
    Arch Intern Med; 1997 Jul; 157(14):1537-44. PubMed ID: 9236555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Converging epidemics: HIV and hepatitis C coinfection.
    Lusk H
    Focus; 2006 May; 21(5):1-5. PubMed ID: 16838423
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.
    Zibert A; Schreier E; Roggendorf M
    Virology; 1995 Apr; 208(2):653-61. PubMed ID: 7538251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of virologic assays in the diagnosis and management of hepatitis C virus infection.
    Chevaliez S; Pawlotsky JM
    Clin Liver Dis; 2005 Aug; 9(3):371-82, v. PubMed ID: 16023971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age?
    Matheï C; Buntinx F; Van Damme P
    J Infect Dis; 2001 Sep; 184(5):659-60. PubMed ID: 11494175
    [No Abstract]   [Full Text] [Related]  

  • 20. [Acute hepatitis due to hepatitis C virus infection in the adult population].
    Hernández Febles M; Rodríguez San Román JL; Martín Suárez JM; Pena-López MJ
    Gastroenterol Hepatol; 2009 Dec; 32(10):677-80. PubMed ID: 19815311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.